ATE552503T1 - Ctgf als biomarker, therapeutisches und diagnostisches ziel - Google Patents

Ctgf als biomarker, therapeutisches und diagnostisches ziel

Info

Publication number
ATE552503T1
ATE552503T1 AT07818669T AT07818669T ATE552503T1 AT E552503 T1 ATE552503 T1 AT E552503T1 AT 07818669 T AT07818669 T AT 07818669T AT 07818669 T AT07818669 T AT 07818669T AT E552503 T1 ATE552503 T1 AT E552503T1
Authority
AT
Austria
Prior art keywords
ctgf
diseases
biomarrker
therapeutic
diagnostic target
Prior art date
Application number
AT07818669T
Other languages
English (en)
Inventor
Stefan Golz
Holger Summer
Andreas Geerts
Ulf Brueggemeier
Barbara Albrecht-Kuepper
Martina Klein
Sonja Steppan
Peter Ellinghaus
Urso Donatella D
Michael Seewald
Hendrik Milting
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of ATE552503T1 publication Critical patent/ATE552503T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
AT07818669T 2006-10-16 2007-10-04 Ctgf als biomarker, therapeutisches und diagnostisches ziel ATE552503T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06021596 2006-10-16
PCT/EP2007/008590 WO2008046517A1 (en) 2006-10-16 2007-10-04 Ctgf as a biomarker, therapeutic and diagnostic target

Publications (1)

Publication Number Publication Date
ATE552503T1 true ATE552503T1 (de) 2012-04-15

Family

ID=38895778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07818669T ATE552503T1 (de) 2006-10-16 2007-10-04 Ctgf als biomarker, therapeutisches und diagnostisches ziel

Country Status (5)

Country Link
US (1) US20110111394A1 (de)
EP (1) EP2074429B1 (de)
AT (1) ATE552503T1 (de)
ES (1) ES2383235T3 (de)
WO (1) WO2008046517A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601660A (en) 2008-08-25 2014-05-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
KR101187814B1 (ko) 2010-03-22 2012-10-08 광주과학기술원 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
WO2018149929A1 (en) * 2017-02-16 2018-08-23 Bayer Pharma Aktiengesellschaft Combination of reporter gene assays and transcriptional analysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE485834T1 (de) 1998-09-08 2010-11-15 Ford Henry Health System Verfahren zum nachweis von bindegewebswachstumsfaktor zur diagnose von nierkrankheiten
US20030113816A1 (en) 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
EP1720562A4 (de) 2004-01-15 2009-10-28 Scios Inc Verfahren zur behandlung von kardialer remodellierung nach myokardschädigung

Also Published As

Publication number Publication date
EP2074429A1 (de) 2009-07-01
EP2074429B1 (de) 2012-04-04
ES2383235T3 (es) 2012-06-19
WO2008046517A1 (en) 2008-04-24
US20110111394A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
WO2008046509A8 (en) Ltbp2 as a biomarker, therapeutic and diagnostic target
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2007070359A3 (en) Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200802428A1 (ru) Комбинации агентов для биологической борьбы и нематоцидов, входящих в покрытие семян
DE602007009095D1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
CL2008000531A1 (es) Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
ATE554091T1 (de) Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
WO2007095601A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2007109107A3 (en) Atf4 as a therapeutic target in alzheimers disease and other neurological disorders
EA200900261A1 (ru) Применение эсцина
BRPI0519919A2 (pt) composições farmacêuticas compreendendo inibidores da nep, inibidores do sistema de produção de endotelina endógena e inibidores da hmg coa redutase
ATE552503T1 (de) Ctgf als biomarker, therapeutisches und diagnostisches ziel